WO2008047391A1 - Nutriceutic composition comprising lactoferrin and proteasic probiotics - Google Patents
Nutriceutic composition comprising lactoferrin and proteasic probiotics Download PDFInfo
- Publication number
- WO2008047391A1 WO2008047391A1 PCT/IT2006/000744 IT2006000744W WO2008047391A1 WO 2008047391 A1 WO2008047391 A1 WO 2008047391A1 IT 2006000744 W IT2006000744 W IT 2006000744W WO 2008047391 A1 WO2008047391 A1 WO 2008047391A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactoferrin
- probiotics
- proteasic
- nutriceutic
- activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- the present invention relates to the pharmacological sector , and more precisely to a nutriceutic composition comprising lactoferrin and proteasic probiotics usable for the treatment of viral affections and as integrator with anti-oxidant and immunostimulating effect.
- Lactoferrin is a glycoprotein originally isolated from cow's milk as component of whey (whey proteins). Bovine lactoferrin contains 4 glycosylated sites. It is made up of a known sequence of 691 amino acids and is considered a multifunctional glycoprotein that plays an important biological role through the intestinal mucosa. Numerous studies have highlighted its beneficial effects on the immune system, and its antibacterial, antiviral and anti-inflammatory action.
- Lactoferrin expresses its biological activity when it is split into two bioactive polypeptides: lactoferricin and lactoferricidin.
- lactoferricin B (of bovine origin) is made up of 8 amino acids, whilst lactoferricidin B (of bovine origin) is made up of 25 amino acids.
- polypeptides represent the biologically active form of lactoferrin. They manifest an antibacterial effect in regard both to Gram-negatives and in regard to Gram-positives, due to the fact that they are able to destabilize the bacterial membrane (Vorland L. H., APMIS, 1999, 107: 971-81). Simultaneously, they also exert anti-viral activity in so far as they bind to the receptor sites on the viral surface and at the same time stimulate the immune response following upon infection (Brink W. , LE Magazine, 2000-10) .
- Lactobacillus paracasei subsp. paracasei F19 is a probiotic isolated from the human small intestine, is very stable at variable conditions of pH, and is not degraded by gastric juices and biliar secretions (Patent No. US6599504) .
- said probiotic When administered, said probiotic not only reinforces the intestinal bacterial flora but, thanks to its antibacterial, immunomodulating and anti-oxidant properties, exerts a beneficial effect on various disorders of the gastro-intestinal apparatus. It has moreover been demonstrated that, when administered with antibiotics, it prevents development of resistant bacteria in the intestinal tract (Sulliven, A. et al., JAC, 2004, 54: 4, 791-797).
- lactobacillus paracasei subsp. paracasei F19 has proven simple to use in so far as it is able to ferment the majority of carbohydrates, including lactose, galactose, tagatose, galacto-oligosaccharides, oligosaccharides, lactulose and all the carbohydrates present in milk and in its derivatives. Furthermore, its use in the food sector improves the organoleptic properties of the products that contain it (Ohlson, K. et al. r Micr. Ecol. Health. Dis., 2002, 3: 27-32).
- lactoferrin is rendered bioavailable and pharmacologically active by the scission of its active components lactoferricin and lactoferricidin.
- lactoferrin is rendered bioavailable and pharmacologically active by the scission of its active components lactoferricin and lactoferricidin.
- lactoferrin is pharmacologically active at the moment of use.
- lactoferrin and probiotics having proteasic activity such as lactobacillus paracasei subsp. paracasei F19
- lactobacillus paracasei subsp. paracasei F19 can ferment and degrade many prebiotics, such as lactoferrin and its bioactive components lactoferricin and lactoferricidin, since it is able to synthesise proteases of a medium-to-high quality that exert a proteolytic action on amylopectin, insulin and glycoproteins.
- probiotics with proteasic activity have the function of physiological starters, catalysing the conversion of lactoferrin into lactoferricin and lactoferricidin.
- probiotics with proteasic activity and lactoferrin in addition to rendering the latter bioavailable, exerts a beneficial and synergistic effect, maximizing the antimicrobial, antibacterial, antiviral, immunomodulatory, antioxidant and anti-inflammatory activity of both of the components .
- composition comprising lactoferrin and probiotics capable of synthesising proteases, such as lactobacillus paracasei subsp. paracasei F19, for the preparation of a medicament usable for the treatment of disorders of the gastro-intestinal apparatus, including chronic hepatites and chronic inflammatory states of the intestine, and disorders due to viral affections of the gastro-intestinal apparatus, of the urogenital apparatus, and of the airways.
- proteases such as lactobacillus paracasei subsp. paracasei F19
- lactoferrin in order for lactoferrin to be effectively split into lactoferricin and lactoferricidin, it must be present in an amount of
- the amount of lactoferrin considered functional ranges from a minimum of 25 mg to a maximum of 150 mg per dose.
- the amount of probiotics with proteasic activity ranges from a minimum of 3 billion living cells at the origin up to 15 billion living cells at the origin per dose .
- the average daily dose is 50 mg of lactoferrin and ⁇ billion living cells at the origin of probiotics with proteasic activity.
- the composition is in the form of a kit for combined extemporary use, which comprises a solution in which lactoferrin and the proteasic probiotics are dissolved at the moment of use.
- said kit is in the form of a bottle containing the solution of stabilizers with a basis of natural fluid extracts, having a dosing top containing lactoferrin and the proteasic probiotics, preferentially with a homogeneous degree of humidity, in the form of powder.
- Said top is to be unscrewed to release the contents and enable mixing with the solution of the bottle at the moment of administration.
- Further stabilizing components can be added to the powder, in the top, that do not affect the stability and the activity of the proteasic probiotics.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Described herein is a nutriceutic composition comprising lactoferrin and proteasic probiotics usable for the treatment of viral affections and as integrator with anti-oxidant and immunostimulating effect.
Description
NUTRICEUTIC COMPOSITION COMPRISING LACTOFERRIN -S-ND
PROTEASIC PROBIOTICS
*****
The present invention relates to the pharmacological sector , and more precisely to a nutriceutic composition comprising lactoferrin and proteasic probiotics usable for the treatment of viral affections and as integrator with anti-oxidant and immunostimulating effect.
Lactoferrin is a glycoprotein originally isolated from cow's milk as component of whey (whey proteins). Bovine lactoferrin contains 4 glycosylated sites. It is made up of a known sequence of 691 amino acids and is considered a multifunctional glycoprotein that plays an important biological role through the intestinal mucosa. Numerous studies have highlighted its beneficial effects on the immune system, and its antibacterial, antiviral and anti-inflammatory action.
Lactoferrin expresses its biological activity when it is split into two bioactive polypeptides: lactoferricin and lactoferricidin.
In particular, lactoferricin B (of bovine origin) is made up of 8 amino acids, whilst lactoferricidin B (of bovine origin) is made up of 25 amino acids.
These polypeptides represent the biologically active form of lactoferrin. They manifest an antibacterial effect in regard both to Gram-negatives and in regard to Gram-positives, due to the fact that they are able to destabilize the bacterial membrane
(Vorland L. H., APMIS, 1999, 107: 971-81). Simultaneously, they also exert anti-viral activity in so far as they bind to the receptor sites on the viral surface and at the same time stimulate the immune response following upon infection (Brink W. , LE Magazine, 2000-10) .
Lactobacillus paracasei subsp. paracasei F19 is a probiotic isolated from the human small intestine, is very stable at variable conditions of pH, and is not degraded by gastric juices and biliar secretions (Patent No. US6599504) .
When administered, said probiotic not only reinforces the intestinal bacterial flora but, thanks to its antibacterial, immunomodulating and anti-oxidant properties, exerts a beneficial effect on various disorders of the gastro-intestinal apparatus. It has moreover been demonstrated that, when administered with antibiotics, it prevents development of resistant bacteria in the intestinal tract (Sulliven, A. et al., JAC, 2004, 54: 4, 791-797).
Furthermore, unlike other probiotics, lactobacillus paracasei subsp. paracasei F19, has proven simple to use in so far as it is able to ferment the majority of carbohydrates, including lactose, galactose, tagatose, galacto-oligosaccharides, oligosaccharides, lactulose and all the carbohydrates present in milk and in its derivatives. Furthermore, its use in the food sector improves the organoleptic properties of the products that contain it (Ohlson, K.
et al.r Micr. Ecol. Health. Dis., 2002, 3: 27-32).
As described previously, lactoferrin is rendered bioavailable and pharmacologically active by the scission of its active components lactoferricin and lactoferricidin. In the light of this, there becomes necessary the use, in the pharmacological field, of a form of lactoferrin that is pharmacologically active at the moment of use.
In order to solve said problem it has been discovered that the association between lactoferrin and probiotics having proteasic activity, such as lactobacillus paracasei subsp. paracasei F19, enables solution of the problems linked to the bioavailability of lactoferrin itself. In fact, it has been revealed that lactobacillus paracasei subsp. paracasei F19 can ferment and degrade many prebiotics, such as lactoferrin and its bioactive components lactoferricin and lactoferricidin, since it is able to synthesise proteases of a medium-to-high quality that exert a proteolytic action on amylopectin, insulin and glycoproteins.
Consequently, probiotics with proteasic activity have the function of physiological starters, catalysing the conversion of lactoferrin into lactoferricin and lactoferricidin.
Furthermore, the combination between probiotics with proteasic activity and lactoferrin, in addition to rendering the latter bioavailable, exerts a beneficial and synergistic effect, maximizing the antimicrobial,
antibacterial, antiviral, immunomodulatory, antioxidant and anti-inflammatory activity of both of the components .
Consequently, forming a subject of the present invention is a composition comprising lactoferrin and probiotics capable of synthesising proteases, such as lactobacillus paracasei subsp. paracasei F19, for the preparation of a medicament usable for the treatment of disorders of the gastro-intestinal apparatus, including chronic hepatites and chronic inflammatory states of the intestine, and disorders due to viral affections of the gastro-intestinal apparatus, of the urogenital apparatus, and of the airways.
It has further been found that, in order for lactoferrin to be effectively split into lactoferricin and lactoferricidin, it must be present in an amount of
25 mg for every 3 billion living cells at the origin of probiotics with proteasic activity per dose, and said proportion must be respected for quantitatively higher administrations.
In any case, the amount of lactoferrin considered functional ranges from a minimum of 25 mg to a maximum of 150 mg per dose.
The amount of probiotics with proteasic activity, such as lactobacillus paracasei subsp. paracasei F19, ranges from a minimum of 3 billion living cells at the origin up to 15 billion living cells at the origin per dose .
Preferably, the average daily dose is 50 mg of
lactoferrin and β billion living cells at the origin of probiotics with proteasic activity.
In a preferred embodiment, the composition is in the form of a kit for combined extemporary use, which comprises a solution in which lactoferrin and the proteasic probiotics are dissolved at the moment of use. Preferably, said kit is in the form of a bottle containing the solution of stabilizers with a basis of natural fluid extracts, having a dosing top containing lactoferrin and the proteasic probiotics, preferentially with a homogeneous degree of humidity, in the form of powder. Said top is to be unscrewed to release the contents and enable mixing with the solution of the bottle at the moment of administration. Further stabilizing components can be added to the powder, in the top, that do not affect the stability and the activity of the proteasic probiotics.
Claims
1. A nutriceutic composition comprising lactoferrin and probiotics having proteasic activity.
2. The nutriceutic composition according to Claim 1, characterized in that the ratio between the two components is 25 mg of lactoferrin for every 3 billion living cells at the origin, of probiotics having proteasic activity, per dose.
3. The nutriceutic composition according to Claim 1, characterized in that lactoferrin is present in an amount between 25 mg and 150 mg per dose.
4. The nutriceutic composition according to Claim 1, characterized in that the probiotics having proteasic activity are present in an amount between 3 billion living cells at the origin and 15 billion living cells at the origin per dose.
5. The nutriceutic composition according to Claim 1, characterized in that the probiotic having proteasic activity is lactobacillus paracasei subsp. paracasei Fl9.
6. Use of the composition according to any one of the preceding claims for the preparation of a medicament usable for the treatment and prevention of disorders of the gastro-intestinal apparatus, the urogenital apparatus, and the airways, as well as disorders due to viral affections.
7. A medicament according to Claim 6, characterized in that it is administered in a daily dose of 50 mg of lactoferrin and 6 billion living cells at the origin of probiotics having proteasic activity.
8. A kit comprising lactoferrin and probiotics having proteasic activity in combination, according to any one of Claims 1 to 5, for the extemporary preparation of a medicament usable for treatment and prevention of disorders of the gastro-intestinal apparatus, the urogenital apparatus, and the airways, as well as disorders due to viral affections.
9. The kit according to Claim 8, characterized in that it is in the form of a bottle, containing the solution of stabilizers with a basis of natural fluid extracts, having a dosing top containing lactoferrin and the proteasic probiotics in the form of powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IT2006/000744 WO2008047391A1 (en) | 2006-10-17 | 2006-10-17 | Nutriceutic composition comprising lactoferrin and proteasic probiotics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IT2006/000744 WO2008047391A1 (en) | 2006-10-17 | 2006-10-17 | Nutriceutic composition comprising lactoferrin and proteasic probiotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008047391A1 true WO2008047391A1 (en) | 2008-04-24 |
Family
ID=38110211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IT2006/000744 WO2008047391A1 (en) | 2006-10-17 | 2006-10-17 | Nutriceutic composition comprising lactoferrin and proteasic probiotics |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008047391A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2930264A1 (en) * | 2008-04-18 | 2009-10-23 | Gervais Danone Sa | NEW STRAIN OF LACTOBACILLUS PARACASEI SUBSP. PARACASEI WITH ANTIMICROBIAL AND IMMUNOMODULATORY PROPERTIES |
| WO2011051482A1 (en) * | 2009-10-29 | 2011-05-05 | Nestec S.A. | Nutritional compositions comprising lactoferrin and probiotics and kits of parts thereof |
| WO2012091945A1 (en) * | 2010-12-29 | 2012-07-05 | Mead Johnson Nutrition Company | Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions |
| WO2012091946A3 (en) * | 2010-12-29 | 2012-09-07 | Mead Johnson Nutrition Company | Method for inhibiting pathogens using a nutritional composition |
| US8648036B2 (en) | 2010-12-29 | 2014-02-11 | Mead Johnson Nutrition Company | Use of nutritional compositions including lactoferrin and one or more prebiotics in inhibiting adhesion of pathogens in the gastrointestinal tract |
| US8968722B2 (en) | 2010-12-29 | 2015-03-03 | Mead Johnson Nutrition Company | Milk-based nutritional compositions containing lactoferrin and uses thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01221319A (en) * | 1988-03-01 | 1989-09-04 | Morinaga Milk Ind Co Ltd | Composition for promoting enteral colonization -of useful bacteria and method therefor |
| EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
| WO1999029833A1 (en) * | 1997-12-08 | 1999-06-17 | Arlafoods Amba | Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain |
| WO2000072874A1 (en) * | 1999-05-28 | 2000-12-07 | Naidu A Satyanarayan | IMMOBILIZED LACTOFERRIN (Im-LF) ANTIMICROBIAL AGENTS AND USES THEREOF |
| EP1082964A1 (en) * | 1998-06-05 | 2001-03-14 | Wakamoto Pharmaceutical Co., Ltd. | Lactic acid bacterium-containing compositions, drugs and foods |
| US6241983B1 (en) * | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
| WO2002043753A1 (en) * | 2000-11-30 | 2002-06-06 | Morinaga Milk Industry Co., Ltd. | Remedies for chronic hepatitis b |
| JP2002332242A (en) * | 2001-03-09 | 2002-11-22 | Morinaga Milk Ind Co Ltd | Therapeutic agent of chronic viral hepatitis type c |
| WO2004028460A2 (en) * | 2002-09-26 | 2004-04-08 | Probiohealth, Llc | Prebiotic and preservative uses of oil-emulsified probiotic encapsulations |
| US20060057131A1 (en) * | 2001-12-20 | 2006-03-16 | Eric Simard | Malleable protein matrix and uses thereof |
-
2006
- 2006-10-17 WO PCT/IT2006/000744 patent/WO2008047391A1/en active Application Filing
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01221319A (en) * | 1988-03-01 | 1989-09-04 | Morinaga Milk Ind Co Ltd | Composition for promoting enteral colonization -of useful bacteria and method therefor |
| US6241983B1 (en) * | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
| EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
| WO1999029833A1 (en) * | 1997-12-08 | 1999-06-17 | Arlafoods Amba | Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain |
| EP1082964A1 (en) * | 1998-06-05 | 2001-03-14 | Wakamoto Pharmaceutical Co., Ltd. | Lactic acid bacterium-containing compositions, drugs and foods |
| WO2000072874A1 (en) * | 1999-05-28 | 2000-12-07 | Naidu A Satyanarayan | IMMOBILIZED LACTOFERRIN (Im-LF) ANTIMICROBIAL AGENTS AND USES THEREOF |
| WO2002043753A1 (en) * | 2000-11-30 | 2002-06-06 | Morinaga Milk Industry Co., Ltd. | Remedies for chronic hepatitis b |
| JP2002332242A (en) * | 2001-03-09 | 2002-11-22 | Morinaga Milk Ind Co Ltd | Therapeutic agent of chronic viral hepatitis type c |
| US20060057131A1 (en) * | 2001-12-20 | 2006-03-16 | Eric Simard | Malleable protein matrix and uses thereof |
| WO2004028460A2 (en) * | 2002-09-26 | 2004-04-08 | Probiohealth, Llc | Prebiotic and preservative uses of oil-emulsified probiotic encapsulations |
Non-Patent Citations (5)
| Title |
|---|
| DATABASE WPI Week 198941, Derwent World Patents Index; AN 1989-297796, XP002437933 * |
| DATABASE WPI Week 200251, Derwent World Patents Index; AN 2002-480009, XP002437932 * |
| DATABASE WPI Week 200339, Derwent World Patents Index; AN 2003-407351, XP002437931 * |
| GRIFFITHS E A ET AL: "In vitro growth responses of bifidobacteria and enteropathogens to bovine and human lactoferrin", DIGESTIVE DISEASES AND SCIENCES, PLENUM PUBLISHING CO, US, vol. 48, no. 7, July 2003 (2003-07-01), pages 1324 - 1332, XP002325929, ISSN: 0163-2116 * |
| VORLAND L H: "LACTOFERRIN: A MULTIFUNCTIONAL GLYCOPROTEIN", APMIS, COPENHAGEN, DK, vol. 107, no. 11, 1999, pages 971 - 981, XP000876672, ISSN: 0903-4641 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8557561B2 (en) | 2008-04-18 | 2013-10-15 | Compagnie Gervais Danone | Strain of Lactobacillus paracasei having antimicrobial and immunomodulatory properties |
| WO2009130423A2 (en) * | 2008-04-18 | 2009-10-29 | Compagnie Gervais Danone | Novel strain of lactobacillus paracasei subspecies paracasei having antimicrobial and immunomodulatory properties |
| WO2009130423A3 (en) * | 2008-04-18 | 2009-12-17 | Compagnie Gervais Danone | Novel strain of lactobacillus paracasei subspecies paracasei having antimicrobial and immunomodulatory properties |
| FR2930264A1 (en) * | 2008-04-18 | 2009-10-23 | Gervais Danone Sa | NEW STRAIN OF LACTOBACILLUS PARACASEI SUBSP. PARACASEI WITH ANTIMICROBIAL AND IMMUNOMODULATORY PROPERTIES |
| KR101609401B1 (en) | 2008-04-18 | 2016-04-05 | 꽁빠니 자베 다노느 | Novel strain of lactobacillus paracasei subspecies paracasei having antimicrobial and immunomodulatory properties |
| WO2011051482A1 (en) * | 2009-10-29 | 2011-05-05 | Nestec S.A. | Nutritional compositions comprising lactoferrin and probiotics and kits of parts thereof |
| AU2010311325B2 (en) * | 2009-10-29 | 2014-11-20 | Société des Produits Nestlé S.A. | Nutritional compositions comprising lactoferrin and probiotics and kits of parts thereof |
| RU2543815C2 (en) * | 2009-10-29 | 2015-03-10 | Нестек С.А. | Nutritional compositions containing lactoferrin and probiotics and sets of their parts |
| WO2012091946A3 (en) * | 2010-12-29 | 2012-09-07 | Mead Johnson Nutrition Company | Method for inhibiting pathogens using a nutritional composition |
| US8648036B2 (en) | 2010-12-29 | 2014-02-11 | Mead Johnson Nutrition Company | Use of nutritional compositions including lactoferrin and one or more prebiotics in inhibiting adhesion of pathogens in the gastrointestinal tract |
| US8968722B2 (en) | 2010-12-29 | 2015-03-03 | Mead Johnson Nutrition Company | Milk-based nutritional compositions containing lactoferrin and uses thereof |
| WO2012091945A1 (en) * | 2010-12-29 | 2012-07-05 | Mead Johnson Nutrition Company | Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions |
| US9737089B2 (en) | 2010-12-29 | 2017-08-22 | Mead Johnson Nutrition Company | Milk-based nutritional compositions containing lactoferrin and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davoodi et al. | Health-related aspects of milk proteins | |
| Playne et al. | Functional dairy foods and ingredients | |
| JP5728512B2 (en) | Composition containing dipeptide as active ingredient | |
| US7794744B2 (en) | Nutritional modules | |
| TW200803751A (en) | Use of a protein hydrolysate for enhancing activity of glucagon-like peptide-1 | |
| WO2008047391A1 (en) | Nutriceutic composition comprising lactoferrin and proteasic probiotics | |
| WO2011122937A1 (en) | Pea protein peptides with anti helicobacter pylori activity | |
| Kassem | Future challenges of whey proteins | |
| WO2015194070A1 (en) | Composition with high content of cyclic dipeptide | |
| KR20050089018A (en) | Sustained improver of muscular fatigue | |
| JP2023011739A (en) | Fermented milk for promoting elevation of amino acid concentration in blood | |
| JP3853673B2 (en) | Treatment for chronic hepatitis C | |
| JPWO2020009135A1 (en) | Anti-influenza virus agent to control the aggravation of influenza | |
| JP2011519896A (en) | Sialic acid to aid salivation | |
| WO2013094250A1 (en) | Bifidobacterium proliferation promoter | |
| JPWO2009057287A1 (en) | Food material for inhibiting osteoclast formation | |
| JP5971893B2 (en) | Mineral absorption improver | |
| TWI620505B (en) | Yoghurt and method of manufacturing same | |
| WO2019058609A1 (en) | Composition for promoting energy consumption | |
| WO2023176951A1 (en) | Collinsella bacteria proliferation controlling composition and use thereof | |
| TWI620509B (en) | Use of beverage and method of manufacturing same | |
| TWI745454B (en) | Composition for inhibiting the reduction of Lactobacillus spp. lactic acid bacteria in the intestinal tract | |
| JP2004115509A (en) | Osteoprotegerin inhibitory factor production promoter | |
| JP4059532B2 (en) | Peptide mixture that prevents intestinal bacteria from entering the body, and a composition containing this peptide mixture | |
| TWI626009B (en) | Use of milk powder and method of manufacturing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06821736 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06821736 Country of ref document: EP Kind code of ref document: A1 |